Stratifikasi Risiko Kematian Jantung Mendadak pada Sindrom Koroner Akut by Endang, Jusup et al.
98
 
Jurnal
Kardiologi IndonesiaJ Kardiol Indones. 2013;34:98-104
ISSN 0126/3773 Case Report
Jurnal Kardiologi Indonesia •  Vol. 34, No. 2 • April - Juni 2013
Risk Stratification of Short Term Sudden Death after 
Acute Coronary Syndrome 
Jusup Endang, Dewi H Suprobo, Radityo Prakoso, 
Yoga Yuniadi, Bambang B Siswanto, Nani Hersunarti
Sudden cardiac death is the leading cause of cardiovascular mortality in acute coronary syndrome. Risk stratification scoring tools are available to better identify patients at risk after acute myocardial infarction. In addition plenty of factors and treatment modalities modulate the risk of sudden 
cardiac death. A case of in-hospital SCD in a young woman with acute anterior STEMI is presented as a trigger to the importance of risk stratification and treatment according to guidelines in preventing SCD.
(J Kardiol Indones. 2013;34:98-104)
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Kematian jantung mendadak merupakan penyebab penting mortalitas kardiovaskular pada sindrom koroner akut. Terdapat 
beberapa sistem stratifikasi risiko yang sudah mapan yang dapat mengidentifikasi lebih baik pasien dengan risiko kematian 
jantung mendadak. Selain itu banyak faktor-faktor lain dan modalitas terapi yang dapat mengubah risiko kematian jantung 
mendadak.
Ditampilkan suatu kasus kematian jantung mendadak pada perempuan muda dengan STEMI anterior sebagai pencetus dis-
kusi pentingnya stratifikasi risiko dan terapi yang sesuai dengan petunjuk baku untuk mencegah kematian jantung mendadak 
pasca infark.
(J Kardiol Indones. 2013;34:98-104)
Kata kunci: kematian jantung mendadak, stratifikasi risiko 
Stratifikasi Risiko Kematian Jantung Mendadak 
pada Sindrom Koroner Akut 
Jusup Endang, Dewi H Suprobo, Radityo Prakoso, 
Yoga Yuniadi, Bambang B Siswanto, Nani Hersunarti
Introduction
S
udden cardiac death (SCD) is the leading 
cause of cardiovascular mortality in developed 
countries. In USA, incidence of SCD up to 
310,000 events per year or about  455 - 870 
per day. It was one case every 2 - 3 minutes.1
Coronary artery disease is present in 80 - 85% of 
patients who experience SCD.2 Patients with CAD 
who have had an acute myocardial infarction (MI) 
are at increased risk for SCD, most often due to a 
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ventricular tachyarrhythmia. However, not all post-
MI patients have the same risk of SCD. Thus, the 
therapeutic approach to prevent SCD depends upon 
the identification of those patients who are most 
likely to have a ventricular tachyarrhythmia and the 
effectiveness of the available preventive measures. 
The process of risk stratification in a patient who 
has had an acute MI has two components: (1) early 
in-hospital identification of patients at increased risk 
for recurrent ischemic events and (2) identification 
of patients at increased risk for arrhythmic or non-
arrhythmic death.3 
There are a number of diagnostic parameters 
such as low left ventricular ejection (EF <30 %), 
myocardial infarction, onset and early phase, low 
heart rate variability, abnormal signal-averaged 
electrocardiograms, T wave alternans, and diabetes 
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mellitus, which, if present, indicate an increased risk 
for SCD.
In National Cardiac Center Harapan Kita, there 
were 18 registered cases of in-hospital SCD from 2006 
to 2010. And there were 204 registered cases of death 
on arrival from 2006 to 2010. This case report is aimed 
to discuss the risk of in-hospital SCD after acute  MI 
with acute heart failure syndrome and uncontrolled 
blood glucose in type 2 diabetes mellitus.
Case Illustration
A 42 years old woman referred from Serang Regional 
General Hospital with acute MI and uncontrolled 
blood glucose in type 2 diabetes mellitus.  She 
complained of chest pain since 5 days before 
admission, described the pain as a heavy-pressure and 
radiated to her back. The pain began right after he was 
awoke in the morning and lasted for over 30 minutes. 
She felt nauseous and diaphoresis as well. This feeling 
lead her to Serang Regional General Hospital which 
then she was diagnosed to have acute anterior MI and 
uncontrolled blood glucose in type 2 diabetes mellitus. 
After one day of treatment in ICU the patient was then 
referred to National Cardiovascular Center Harapan 
Kita (NCVCHK). When arrived in the emergency 
unit, the patient still felt chest pain. Risk factors for 
coronary artery disease are hypertension, diabetes 
mellitus and dyslipidemia.
 On physical examination, patient was alert and looked 
moderately ill, her blood pressure was 116/83 mmHg, 
heart rate of 124 bpm regullar and with adequate 
volume and respiratory rate  of 22 per minute, and 
peripheral saturation on oxymetri was 96%. His 
conjunctiva was not pale and sclera was not icteric. His 
jugular venous pressure was 5+2 cmH
2
O, and from the 
heart examination his first and second heart sound were 
normal and no murmur or gallop. Rales was heard over 
the half of the both lung fields without any wheezing. 
The abdomen was supple, no enlargement of the liver 
or the spleen, with normal peristaltic sound. His both 
lower extremities were warm and not swollen with 
good and equal pulsation on both sides.
ECG (Figure 1 A) showed sinus tachycardia, axis 
LAD, QRS rate 124x/minutes, pathologic Q waves at 
V1-V3, poor R progression II, III, aVF, V4-V6 with 
ST elevation V1-V4 and the chest x-ray (Figure 1 B) 
showed enlarged heart with CTR of 60% (not maximal 
inspiration), normal aortic and pulmonic segment, 
without any sign of congestion and infiltrate.
The laboratory examination on admission revealed 
random glucose test of 298 mg/dl, CKMB of 258 
U/L, Trop T of 3.59 ng/ml, Total cholesterol 196 mg/
dl, HDL Cholesterol 50 mg/dl, LDL Cholesterol 98 
mg/dl, Trigliseride 204 mg/dl, Ratio Cholesterol 3.93 
mg/dl, uric acid 8.7 mg/dl and other measures were 
within normal limit.
She was diagnosed as suffered from Acute antero-
septal STEMI day 5 Killip II without revascularization, 
Type 2 Diabetes Mellitus, and Pneumonia. Calculated 
TIMI risk score was 7/14. Then following treatment 
were given: fondaparinux 2.5mg sub cutaneously, 
RI infusion drip start at 2 iu/hour, ASA 80 mg OD, 
Clopidogrel 75 mg OD, Atorvastatin 20 mg OD, 
Captopril 6.25 mg tid, ISDN 5 mg tid, NTG infusion 
Figure 1 A. 12-leads ECG    B. Supine AP Chest X’Ray
Endang J dkk: Kematian mendadak pada sindrom koroner akut
101Jurnal Kardiologi Indonesia •  Vol. 34, No. 2 • April - Juni 2013
B
start 0.5mg/hour. She was sent to  the intensive 
cardiovascular care unit (CVCU). However, due to 
refractory heart failure with low EF (20-30%) and signs 
low cardiac output syndrome then intra aortic balloon 
counterpulsation (IABP) was inserted and dobutamin 
was given as well. Lung infection could be controlled 
with imipenem 1 g IV twice a day. She underwent 
early revascularization which found normal left main 
coronary artery, small RCA, total occlusion at proximal 
LAD and  normal LCX. Then a long drug eluting 
stent 3.0/38mm was implanted at proximal LAD and 
another bare metal stent 2.5/30 mm at mid LAD with 
good results. The blood glucose level ranged from 70 
to 325 g/dL with syntax score of 29.5.
Four day later  the patient’s condition improved 
with stable hemodynamic state and the infection 
recovered. The inotropic and vasopressor drugs weaned 
and the IABP was removed. Patient moved to ward 
and starts mobilization. Her measured body weight 
was 52 kgs.
Echocardiography reevaluation showed LV 
dilatatian (EDD of 55 mm), poor LV systolic 
(EF 22%) and diastolic function with akinetic 
anteroseptal to apical wall, normokinetic  in the 
lateral and posterior base, while other segment 
shown hipokinetic motion with increased of LVEDP. 
The RV function (TAPSE 1.6 cm) was decreased 
with moderate to severe pulmonary hypertension. 
Carvedilol was started on day 9 post MI and 
uptitrated slowly. Unfortunatelly, at 8 pm on day 9 
hospitalization, patient suddenly awake and complain 
of breathlessness and shortly followed by cardiac 
arrest. Cardio pulmonary resuscitation (CPR) last 
for 50 minutes was failed and patient died.
Literature Review and Discussion
Definition
SCD is defined as natural death from cardiac causes, 
heralded by abrupt loss of consciousness within 1 
hour of the onset of an acute change in cardiovascular 
status. Preexisting heart disease may or may not have 
been known to be present, but the time and mode of 
death are unexpected.4
Sudden Cardiac Death in patients with 
Acut e MI
Coronary artery disease is present in 80 - 85% of 
patients who experience SCD.5 Acute MI can be 
defined from a number of different perspectives 
related to clinical, ECG, biochemical, and pathological 
characteristics. Rapid diagnosis and early risk 
stratification of patients presenting with acute chest 
pain are important to identify patients in whom early 
interventions can improve outcome.
There are several predictor of SCD in patient with 
MI, such as GRACE risk score, Killip classification, 
TIMI risk score, heart rate variability, baroreflex 
sensitivity and uncontrolled blood glucose in type 2 
diabetes mellitus .
In-hospital Mortality Risk Scoring Tools
 
GRACE study5 showed 1989 patients died in hospital, 
1466 died between discharge and six month follow-
up, and 2793 suffered a new non-fatal myocardial 
infarction. Nine factors independently predicted death 
A BC
Figure 2 A. coroangiography show total occlusion at proximal LAD, B. Flow to LAD after recanalization with 
wire. C. After PCI at proximal and mid part LAD.
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and the combined end point of death or MI in the 
period from admission to six months after discharge are 
age, development (or history) of heart failure, peripheral 
vascular disease, systolic blood pressure, Killip class, 
initial serum creatinine concentration, elevated initial 
cardiac markers, cardiac arrest on admission, and ST 
segment deviation. The simplified model was robust, 
with prospectively validated C-statistics of 0.81 for 
predicting death and 0.73 for death or myocardial 
infarction from admission to six months after discharge. 
The external applicability of the model was validated in 
the dataset from GUSTO (Global Use of Strategies to 
Open Occluded Coronary Arteries) IIb trial.6
Fox et al. stated that older age, higher Killip class, 
elevated heart rate, lower systolic blood pressure, and 
anterior location of the infarct have been identified as 
the most important independent predictors of early 
mortality in clinical trials and registries.7 
The Killip classification is a classification system 
used in individuals with an acute MI, in order to risk 
stratify them. Individuals with a low Killip class are less 
likely to die within the first 30 days after their MI than 
individuals with a high killip class. High Killip class 
was independent predictors of mortality in STEMI 
and non-STEMI patients.8 
David et al. found that the TIMI risk score 
for STEMI captures the majority of prognostic 
information offered by a full logistic regression model 
but is more readily used at the bedside. This risk 
assessment tool is likely to be clinically useful in the 
triage and management of fibrinolytic-eligible patients 
with STEMI. Careful risk assessment for each patient 
informs decisions regarding therapeutic interventions, 
triage among alternative levels of hospital care, and 
allocation of clinical resources.9 
Our patient had Killip class II, elevated heart rate, 
low systolic blood pressure, weight of less than 67 kgs, 
diabetes, history of hypertension, time to appropriate 
treatment of 5 days and infarct in the anterior wall, 
and TIMI risk score of 8/14.  GRACE risk score 
calculation revealed that probability of  in hospital 
mortality of 17% and death or MI of 40% a. TIMI 
risk score showed the probability of 26.8 mortality 
rate in 30 days. From these analyses, this patient had 
a very high risk of SCD.
Out of risk stratification tools, some factors are 
atributed to SCD in this particular patient. A strong 
relationship was found between LVEF and SCD 
which is higher with varying degrees of left ventricular 
dysfunction. 
Beta-blockers in acute MI and LV 
dysfunction
Because of their initial transient negative inotropic 
effects, beta-blockers traditionally were considered 
contraindicated in HF. However, in CAPRICORN 
study,10 carvedilol reduced mortality and reinfarction 
in post-MI patients with left ventricular systolic 
dysfunction, with or without signs of HF. In our 
case, carvedilol was initiated at day 5 after MI and 
uptitrated slowly which is relevant to CAPRICORN 
subject. As LVEF of patient was only 22%, uptitration 
Figure 3 GRACE risk score calculator of the particular 
patient showed in hospital probability of death was 17%, 
and probability of composite death and MI was 40%.
Figure 4. Killip classification of Acute MI predicting 30-
day mortality.8
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of carvedilol was done very cautiosly. Whether the 
benefit of carvedilol has not yet achieved after 3-4 
days administration is not clear. In systematic review 
of 11 randomized control trial involving more than 
5000 patients with acute MI and heart failure, 
carvedilol significantly reduced all-cause mortality 
compare to commonly prescribed beta-blocker.11 
Present guidelines advise that in patients with systolic 
HF, most of whom have coronary artery disease, an 
ACE inhibitor should be used first, and a beta-blocker 
such as carvedilol or metoprolol should be started 
at low doses and gradually increased over 12 weeks. 
There is now conclusive evidence that long-term beta-
blocker use results in improved rates of mortality and 
morbidity in patients with HF.
Implantable Cardioverter Defibrilator
The Multicenter Autonomic Defibrillator Implanta-
tion Trial II (MADIT II) trial12 confirm a survival 
benefit from implantable cardioverter defibrillator 
(ICD) implantation in a vastly enlarged group of 
patients, those with any history of MI (at least 30 
days) and left ventricular dysfunction with an ejection 
fraction (EF) of 30% or less. Although our patient had 
low EF (EF 22%), but she only 9 days after MI. That’s 
why she was not yet indicated for ICD.
Diabetes melitus
Diabetes mellitus is a major risk factor for cardiovas-
cular disease in general and for coronary heart disease 
in particular. Furthermore, the recent National 
Cholesterol Education Program III guidelines have 
elevated diabetes to a coronary disease risk equivalent. 
Among patients with diabetes who survived from 
MI, less is known about subsequent morbidity 
and mortality. Up to 20% of all patients with an 
infarction have diabetes, and this figure is expected 
to increase.9 Importantly, patients with diabetes may 
present with atypical symptoms, and heart failure 
is a common complication. Diabetic patients who 
survive from STEMI still have doubled mortality 
risk as compared with non-diabetic patients. Our 
patient has uncontrolled blood glucose in type 2 
diabetes mellitus despite insulin infusion 2-3 mg/
hour. Poor control of blood glucose may increased 
the event of SCD.
Summary
The risk of SCD is higher in patient with MI with 
heart failure and low EF,  higher GRACE risk score, 
higher TIMI risk score, higher Killip class, late onset of 
treatment, and uncontrolled blood glucose in diabetic 
patient.
We reported a case of SCD on day 5 of acute 
anterior STEMI with TIMI risk of 8/14 and  Killip 
class II who underwent early PCI. Patient has low 
ejection fraction, and uncontrolled blood glucose 
level. 
From this case we learn that intensive glucose 
control with insulin in patients with significant 
hyperglycaemia (>9.9mmol) is mandatory, regardless of 
prior diabetes history (level of evidence B). The Scottish 
Figure 5 TIMI risk score for STEMI predicting 30-day mortality. h/o = history of; HTN = hypertension; LBBB = 
left bundle branch block; STE = ST segment elevation; TIMI = Thrombosis In Myocardial Infarction.9 
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Intercollegiate Guidelines Network state that “Patients 
with clinical myocardial infarction and diabetes mellitus 
or marked hyperglycaemia (>11.0mmol/l) should 
have immediate intensive blood glucose control.” This 
should be continued for at least 24 hours.Target glucose 
levels 140 mg/dL (7.8 mmol/L) have been suggested. 
However, care needs to be taken to avoid blood 
glucose levels below 80–90 mg/dL (4.4–5 mmol/L), 
as hypoglycaemia-induced ischaemia might also affect 
outcome in diabetic patients with acute coronary 
syndromes. Uncontrolled blood glucose in non-diabetic 
patient gives higher mortality than uncontrolled blood 
glucose in diabetic patient. Both diabetes mellitus and 
MI affect the baroreflex sensitivity so that it could 
increase the rates of SCD.
Another lesson learnt is that in such high risk 
post MI patient, electrophysiology study should 
be considered to determine the need of ICD 
implantation earlier. The analyses from MADIT 
trial revealed that the sicker patients achieved 
better benefit from the ICD.
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